Core Viewpoint - Jichuan Pharmaceutical announced that its wholly-owned subsidiary, Shaanxi Dongke Pharmaceutical Co., Ltd., has received the drug registration certificate for Lidocaine Gel Patch [2] Group 1 - The announcement was made on the evening of September 16 [2] - The drug registration certificate pertains to Lidocaine Gel Patch, indicating a new product approval [2]

Core Viewpoint - Jichuan Pharmaceutical has received approval for its Lidocaine Gel Patch from the National Medical Products Administration, which may enhance its product portfolio and revenue potential [1] Company Summary - Jichuan Pharmaceutical's subsidiary, Shaanxi Dongke Pharmaceutical Co., Ltd., has been granted a drug registration certificate for Lidocaine Gel Patch [1] - As of the latest report, Jichuan Pharmaceutical's market capitalization stands at 23.5 billion yuan [1] Revenue Composition - For the year 2024, Jichuan Pharmaceutical's revenue composition is as follows: - Heat-clearing and detoxifying products: 33.53% - Pediatric products: 28.11% - Digestive products: 14.41% - Other sectors: 9.94% - Respiratory products: 8.13% [1]

Core Viewpoint - Jichuan Pharmaceutical (600566.SH) announced that its wholly-owned subsidiary, Shaanxi Dongke Pharmaceutical Co., Ltd., has received the drug registration certificate for Lidocaine Gel Patch from the National Medical Products Administration [1] Group 1: Company Information - The company is involved in the pharmaceutical industry, specifically focusing on the development and production of local anesthetics [1] - Lidocaine is classified as an amide-type local anesthetic, which functions by stabilizing the nerve cell membrane through the inhibition of ion channels necessary for nerve impulse generation and conduction [1] Group 2: Regulatory Approval - The approval from the National Medical Products Administration signifies a regulatory milestone for the company, allowing it to market the Lidocaine Gel Patch [1]

Core Viewpoint - Jichuan Pharmaceutical's subsidiary, Shaanxi Dongke, has received approval from the National Medical Products Administration for the registration certificate of Lidocaine Gel Patch, which is intended for alleviating postherpetic neuralgia [2] Company Summary - The approval of the Lidocaine Gel Patch is seen as a significant addition to the company's product line, which is expected to positively impact its future development [2] - Currently, there are four companies in China, including Shaanxi Dongke, that have been approved for the Lidocaine Gel Patch [2] Industry Summary - The market development cycle for the newly approved drug may be lengthy and is subject to uncertainties influenced by industry policies and procurement bidding [2]

Core Viewpoint - Jichuan Pharmaceutical (600566.SH) announced that its wholly-owned subsidiary, Shaanxi Dongke Pharmaceutical Co., Ltd., received the drug registration certificate for Lidocaine Gel Patch from the National Medical Products Administration [1] Group 1: Company Information - The drug registration certificate pertains to Lidocaine, an amide local anesthetic that stabilizes nerve cell membranes by inhibiting the ion channels required for nerve impulse generation and conduction [1]

Core Viewpoint - Jichuan Pharmaceutical's subsidiary, Shaanxi Dongke Pharmaceutical, has received approval from the National Medical Products Administration for the registration certificate of Lidocaine Gel Patch, indicating a significant advancement in the company's product portfolio [1] Company Summary - Jichuan Pharmaceutical's subsidiary, Shaanxi Dongke, is now authorized to market Lidocaine, an amide-type local anesthetic, which works by stabilizing nerve cell membranes through the inhibition of ion channels necessary for nerve impulse conduction [1]

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for Lidocaine Gel Patch, indicating a significant regulatory approval for a new product aimed at treating postherpetic neuralgia [1] Group 1: Product Details - The drug is named Lidocaine Gel Patch, classified as a Class 3 chemical drug [1] - The formulation is a patch with dimensions of 14cm x 10cm, containing 14g of gel and 700mg of Lidocaine per patch [1] - The product is specifically indicated for alleviating pain associated with postherpetic neuralgia and is suitable for use on intact skin [1]

Group 1: Company Strategy and Market Positioning - The company is focusing on three key areas for future strategic planning: expanding sales channels, increasing R&D efforts, and optimizing production processes to enhance operational efficiency and shareholder value [2] - The company aims to strengthen its presence in the outpatient market while enhancing brand influence, particularly for the "JiuYue" transdermal patch brand [3] - The company plans to launch several transdermal products, including Lidocaine Gel Patch and Indomethacin Gel Patch, expected to be approved in 2025, and Ketoprofen Patch and Flurbiprofen Patch in 2026 [4] Group 2: Product Development and Competition - The company believes that the market for external anti-inflammatory drugs is currently underserved, and the two products, Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch, will complement each other rather than compete [7] - The Loxoprofen Sodium Gel Patch has a high drug loading of 100mg per patch and is suitable for a wide range of conditions, while the Ketoprofen Gel Patch offers better drug permeability and efficacy for osteoarthritis [5] Group 3: Financial Projections and Market Risks - The company projects a revenue growth of 10-20% for the fiscal year 2025, with a similar expectation for net profit excluding non-recurring items [11][12] - The company acknowledges that its operational plans and product sales depend on various factors, including market conditions and industry policies, which introduce significant uncertainty [12] Group 4: Cost Management and Procurement Strategy - The company plans to reduce sales expenses by optimizing marketing strategies and expanding outpatient market reach [2] - The company maintains an integrated development strategy for raw materials and finished products, ensuring quality control and cost management through in-house production [10]